Li-Xuan Qin, PhD

Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 94 - RISK FACTORS ASSOCIATED WITH SARCOMA RECURRENCE DO NOT REMAIN CONSTANT OVER TIME

  Saturday, November 16, 2024
  1:00 PM – 2:00 PM PST